< Back to all news
10 June 2021

Max Meyer Young Talent in NASH Prize and Max Meyer Research Prize awarded!

Thanks to medical research we have tools against hepatitis B and hepatitis C. We can vaccinate to prevent infection with hepatitis B. We can control with medication chronic hepatitis B. We can cure patients affected with chronic hepatitis C. Now the most frequent  liver disease affecting millions is non-alcoholic steatohepatitis. Medical research still has to find treatment and biomarkers for this disease therefore this is with great pleasure and honor that we are giving prizes to investigators active in this field. The Max Meyer Young Talent in NASH Prize is going to a talented medical student Ms Pauline Fauroux working on biomarkers to better identify patients at risk to progress to cirrhosis. Ms Pauline Fauroux is working in Lyon and due to the pandemic situation is unable to come today to receive in person her prize.

The second prize, the Max Meyer Research Prize is going to Dr Yuly Mendoza for her publication on a simple combination of tests to select patients with advanced liver disease at risk of complications. Dr Mendoza got her MD degree in Colombia and is working for several years in Switzerland for her PhD. We congratulate both of you for your prize and wish you, in name of the Swiss NASH Foundation a lot of success for your future.

For regular update on new research follow our Twitter account: https://twitter.com/swissnash

< Back to all news
4 June 2021

International Nash Day

The International Nash Day organised by the Global Liver Institute (GLI) is coming up on the 10. June 2021 and we are happy to announce that we will take an active part in it!

The theme for the 2021 #NASHday is NASH Around the World!

Please join our global effort to raise awareness about nonalcoholic steatohepatitis (NASH), the advanced form of nonalcoholic fatty liver disease (NAFLD), and the actions that people can take to address this life-threatening disease worldwide. 

If you register for the event you can join different panels on topics like:

  • NASH as a Global Public Health Challenge
  • NASH and Liver Cancer
  • NASH and Obesity
  • Pediatric NASH
  • NASH and Diabetes
  • Beyond the Biopsy: Innovations in Diagnostics
  • NASH in Lean Individuals
  • NASH: A Conversation in the Black Community

Please follow the hashtag #NashDay on Twitter for updates about this event We do appreciate if you follow us @swissnash as well 😉

< Back to all news
2 October 2019

Launched October 2019

The Swiss NASH Foundation was launched in October 2019 in Bern, Switzerland. In a joint effort to tackle the increasing prevalence and burden of NASH, scientific experts and the leading pharmaceutical companies: Gilead, Allergan, Genfit and Intercept have joined forces to establish The Swiss NASH Foundation. NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an under-diagnosed and under-reported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.

In the absence of a cure, the major treatment for NASH remains lifestyle changes including weight reduction, healthy diet and regular physical activity. The Swiss NASH Foundation’s mission is to raise awareness and increase the knowledge about NASH and fatty liver in general. Through funding innovative research projects on NASH diagnostics, treatment and patient management, the foundation is joining the fight against this epidemic disease.

Watch our video to learn more: